tailieunhanh - Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations

The approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic melanoma. Patients carrying a substitution of valine to glutamic acid at codon 600 () or a substitution of valine to leucine () in BRAF show complete or partial response. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN